Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study Abstract #196

Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.
Aim(s): To assess the safety and efficacy of the combination of Streptozotocin and 5-FU.
Materials and methods: A retrospective study has been performed, using the medical records of 146 patients with endocrine pancreatic tumors who received the combination treatment of streptozotocin and 5-FU during the period 1981-2010.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Pantelis Antonodimitrakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#341 Role of Chromogranin A and Neuron-Specific Enolase Biomarkers in Progression-Free Survival (PFS) with Everolimus (EVE) v. Placebo (PB) in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET): Phase III RADIANT-3 Results
Introduction: In previous phase II studies of EVE in patients with pNET, those with elevated baseline Chromogranin A (eCgA) and neuron-specific enolase (eNSE) levels experienced shorter PFS.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Kjell Oberg
Authors: Oberg K, Anthony L, Sideris L, Chen L T, ...
#708 Sunitinib in Pancreatic Neuroendocrine Tumors
Introduction: Sunitinib has shown significant improvement of progression-free survival in patients with advanced pancreatic neuroendocrine tumors (pNET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Harald Lahner
Keywords: sunitinib, pNET
#990 Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors
Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Joerg Schrader
Keywords: chemotherapy
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...